Ivermectin and Covid 19

Ivermectin and Covid-19
Student’s Name
Professor’s name
Institutional affiliation
Course Tittle
Date
Ivermectin and Covid-19
Behera, P. et al. (2021). Role of ivermectin in preventing SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS ONE, 16(2).
The article builds on a hospital-based matched case-control study for exploring the therapeutic and preventive role of ivermectin in SARS-CoV-2 infection. The case-control study involved 186 case-control pairs. The researchers conducted the case-match survey of healthcare workers who tested positive or negative for COVID-19 in India at AIIMS Bhubaneswar. Healthcare workers who tested positive for COVID-19 are the cases and controls for the study, while those who tested negative were the controls. The proposed intervention was the intake of ivermectin and other prophylaxis for COVID-19. The researchers monitored and observed both the cases and controls or level II-2 evidence to highlight their findings on the drug. 76 controls and 41 cases took two doses of ivermectin prevention, and their data collected and recorded for analysis. The results concluded that the administration of the two doses at the interval of 72 hours, each dose weighing 300 μg/kg, resulted in reduced infection among healthcare workers in the facility by 73%.
Babalola, O. E. et al. (2021). Ivermectin shows clinical benefits in mild to moderate COVID19: A randomized controlled, double-blind dose-response study in Lagos. International Journal of Medicine.
The researchers explore the efficacy of ivermectin on people infected with COVID-19 by conducting a range of tests. The research builds on the findings of randomized translational proof of concept, dose-response, controlled double-blind placebo, a parallel-group study of ivermectin efficacy on patients proven to be COVID-19 positive through RT-PCR. The study involved randomized controlled trials on the drug conducted on 62 patients categorized into three treatment groups. The first group received a 6mg regime of ivermectin, 12mg ivermectin regime for the second group, and the third functioned as the control group. Analysis of the randomized controlled trials indicates the efficacy of ivermectin in converting the positive cases to negative, directly proportional to the dosage administered. In essence, the group receiving 12mg of ivermectin regime showed rapid conversion to negativity, proving the efficacy of ivermectin for clinical use in managing SARS-CoV-2 infections.
Chaccour, C. et al. (2021). The effect of early treatment with ivermectin on viral load, symptoms, and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. PlumX Metrics.
The research study evaluates the efficacy of ivermectin on proven patients with non-severe COVID-19 and who do not have underlying conditions or risk factors for the same at the Clinica Universidad de Navarra’s emergency room. It uses randomized controlled trials (RCTs) to showcase the efficacy of one dose of ivermectin to reduce SARS-CoV-2 infections. Patients enrolled in the evaluation showcased early symptoms of the disease upon which the participants were randomly selected to...